维泰瑞隆授予诺华公司独家选择权，以收购其大脑递送平台，同时保留推进选定治疗资产的权利-动脉网

Sironax Grants Novartis Exclusive Option to Acquire its Brain Delivery Platform While Retaining Rights to Advance Selected Therapeutic Assets

CISION 等信源发布 2025-07-09 20:00



可切换为仅中文







WALTHAM, Mass.

马萨诸塞州沃尔瑟姆

，

July 9, 2025

2025年7月9日

/PRNewswire/ -- Sironax, a clinical-stage biotech company dedicated to the discovery and development of transformational therapies for age-related diseases, today announced a strategic agreement with Novartis under which Sironax will grant Novartis an exclusive option to acquire its proprietary Brain Delivery Module (BDM) platform, a differentiated blood-brain-barrier (BBB) crossing technology designed to enhance the brain delivery of therapeutics of various modalities.

/PRNewswire/ -- 专注于发现和开发与年龄相关疾病变革性疗法的临床阶段生物技术公司Sironax今日宣布，与诺华达成一项战略协议。根据协议，Sironax将授予诺华独家选择权，收购其专有的脑部递送模块（BDM）平台。该平台是一项差异化血脑屏障（BBB）穿越技术，旨在增强各种模式治疗药物向大脑的递送能力。

Sironax retains the right to continue developing selected therapeutic assets using the platform. .

Sironax保留继续使用该平台开发选定治疗资产的权利。

'This partnership combines Novartis's global expertise in neuroscience with Sironax's high-quality innovation, maximizing the potential impact of our brain delivery platform,' said Dr.

“这一合作结合了诺华在全球神经科学领域的专业优势与思睿昂的高质量创新，最大化我们大脑递送平台的潜在影响，”博士说道。

Shefali Agarwal

谢法利·阿加瓦尔

, President and CEO of Sironax. 'At the same time, we will continue to explore our targets of interest with the platform and deliver brain-penetrant therapeutics. This strategic alignment empowers Sironax to accelerate its global expansion and clinical development, reinforcing our commitment to redefining what's possible for patients living with serious neurological conditions.'.

，Sironax的总裁兼首席执行官。“同时，我们将继续利用该平台探索我们感兴趣的目标，并提供能够穿透大脑的治疗药物。这一战略调整使Sironax能够加速其全球扩张和临床开发，强化我们对重新定义严重神经系统疾病患者的可能性所作出的承诺。”

'Effectively delivering therapeutics across the blood-brain barrier remains one of the most important challenges in drug discovery,' said

“有效地将治疗药物穿越血脑屏障仍然是药物发现中最重要的挑战之一，”他说。

Robert Baloh

罗伯特·巴洛

, Global Head of Neuroscience, Biomedical Research at Novartis. 'We're excited to enter into this agreement with Sironax to fully explore the promise of the BDM platform, leveraging our deep expertise and capabilities in neuroscience to bring forward next-generation therapies for patients in need.'

诺华生物医学研究全球神经科学主管。“我们很高兴与Sironax达成此项协议，以充分探索BDM平台的潜力，利用我们在神经科学领域的深厚专业知识和能力，为有需要的患者带来下一代疗法。”

Under the terms of the agreement, Novartis will evaluate the BDM platform within an option period. Upon option exercise, Novartis will acquire full global rights to the BDM platform. Sironax is eligible to receive up to

根据协议条款，诺华将在选择权期限内评估BDM平台。在行使选择权后，诺华将获得BDM平台的全球完整权利。Sironax有资格获得高达

$175 million

1.75亿美元

in upfront and near-term payments.

预先支付和近期付款。

About Sironax

关于赛诺哈斯

Sironax is a clinical-stage biotech company focused on the discovery and development of transformational therapies that address the root causes of age-related diseases. The company tackles aging issue by targeting three core drivers: dysregulated cell death, uncontrolled inflammation, and disrupted energy homeostasis.

赛诺亚克斯是一家临床阶段的生物技术公司，专注于发现和开发针对与年龄相关疾病根本原因的变革性疗法。该公司通过靶向三个核心驱动因素来应对衰老问题：细胞死亡失调、不受控制的炎症以及能量稳态的破坏。

To date, Sironax's breakthrough pipeline contains multiple first-in-class and/or potentially best-in-class programs at clinical stage. For more information, please visit our website .

截至目前，士朗生物的突破性研发管线包含多个处于临床阶段的首创和/或潜在最佳同类项目。欲了解更多信息，请访问我们的网站。

https://www.sironax.com

Forward-looking Statements

前瞻性声明

This press release contains forward-looking statements related to the collaboration's potential benefits, which are subject to risks and uncertainties. Actual outcomes may differ based on technical, regulatory, and market factors.

本新闻稿包含关于合作潜在益处的前瞻性声明，这些声明受风险和不确定性的影响。实际结果可能基于技术、监管和市场因素而有所不同。

Contacts:

联系人：

Libin Shang, PhD

商立彬，博士

Vice President, Business Development and Public Affairs

副总裁，业务发展与公共事务

Erik Kopp

埃里克·科普

Executive Director, Corporate Communications

执行董事，企业传播

PR@sironax.com